Genzyme Gets Massachusetts Arthritis Shot Suit Tossed on Appeal

A retired teacher’s claims against Genzyme Corp. over an allegedly flawed arthritis treatment were non-preempted and “parallel,” but her suit nonetheless should have been dismissed because she didn’t support her claims with enough detail, the Massachusetts top court said Friday.

Patricia Dunn alleged “no facts—regulatory, medical, or otherwise—that connect Genzyme’s actions with the purported harm,” Justice Frank M. Gaziano wrote for the Massachusetts Supreme Judicial Court.

The Food and Drug Administration granted premarket approval for Genzyne’s Synvisc-One as a medical device in 2009.

Immediately after receiving Synvisc-One injections in each knee in 2015, Dunn began to experience pain, difficulty walking, ...